Product Information
COBENFY 125 MG-30 MG CAPSULE is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $30.2302 per EA under NDC 00003012560. Its NADAC has been published 81 times since Mar 19, 2025.
FDA first approved this application on Sep 26, 2024.
Strength
30; 125 mg/1; mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003012560
Classification
Brand
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TROSPIUM CHLORIDE; XANOMELINEApproval Type
New Drug (NDA)
FDA Application
NDA216158FDA Approved
9/26/2024
On Market Since
9/27/2024
Pharmacological Classes
Price Statistics
The NADAC for COBENFY 125 MG-30 MG CAPSULE has been published 81 times since Mar 19, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $30.2302 per EA |
|---|---|
| All-time high | $30.3223 (May 13, 2026) |
| All-time low | $29.6004 (Apr 23, 2025) |
| 52-week high | $30.3223 |
| 52-week low | $29.6639 |
| Median price | $29.7277 |
| Average price | $29.9497 |
| Largest weekly change | +2.0% (Jan 14, 2026) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the xanomeline and trospium chloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
xanomeline and trospium chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COBENFY 125 MG-30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for COBENFY 125 MG-30 MG CAPSULE, manufactured by E.R. Squibb & Sons, L.L.C., is $30.2302 per EA (NDC 00003012560), effective Sep 30, 2026.
How has the price of COBENFY 125 MG-30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for COBENFY 125 MG-30 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for COBENFY 125 MG-30 MG CAPSULE?
Since Mar 19, 2025, the NADAC for COBENFY 125 MG-30 MG CAPSULE has ranged from a low of $29.6004 (Apr 23, 2025) to a high of $30.3223 (May 13, 2026), with a median of $29.7277 per EA.
Are there cheaper alternatives to COBENFY 125 MG-30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of COBENFY 125 MG-30 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COBENFY 125 MG-30 MG CAPSULE?
COBENFY 125 MG-30 MG CAPSULE (NDC 00003012560) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.